5-(tert-Butyl)-2-ethoxy-1,3-diphenyl-2,3-dihydro-1H-imidazo[4,5-b]pyrazine

Catalog No. :
ACHFLQ827
CAS No. :
1643842-87-8
Molecular Formula :
C23H26N4O
Molecular Weight :
374.49

IUPAC Name:5-(tert-butyl)-2-ethoxy-1,3-diphenyl-2,3-dihydro-1H-imidazo[4,5-b]pyrazine

5-(tert-Butyl)-2-ethoxy-1,3-diphenyl-2,3-dihydro-1H-imidazo[4,5-b]pyrazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-(tert-Butyl)-2-ethoxy-1,3-diphenyl-2,3-dihydro-1H-imidazo[4,5-b]pyrazine
IUPAC Name5-(tert-butyl)-2-ethoxy-1,3-diphenyl-2,3-dihydro-1H-imidazo[4,5-b]pyrazine
Molecular FormulaC23H26N4O
Molecular Weight374.49
SMILESCCOC1N(C2=CC=CC=C2)C3=NC=C(C(C)(C)C)N=C3N1C4=CC=CC=C4
InChI KeyKELYQVPZTMKPHB-UHFFFAOYSA-N
Synonym1H-Imidazo[4,5-b]pyrazine, 5-(1,1-dimethylethyl)-2-ethoxy-2,3-dihydro-1,3-diphenyl-;5-(tert-butyl)-2-ethoxy-1,3-diphenyl-2,3-dihydro-1H-imidazo[4,5-b]pyrazine;5-(1,1-Dimethylethyl)-2-ethoxy-2,3-dihydro-1,3-diphenyl-1H-imidazo[4,5-b]pyrazine
CAS No.1643842-87-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACHFLQ827 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACHFLQ827 route product structure diagram
    ACHFLQ8271643842-87-8
Inquiry

2. ACHFLQ827 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACTRMX927 route compound structure diagram
    ACTRMX927555-75-9
  4. Then
  5. ACHFLQ827 route product structure diagram
    ACHFLQ8271643842-87-8
Inquiry

Comments (0)